Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 8, 2007

NimbleGen Licenses OGT’s Oligonucleotide Patents

  • NimbleGen Systems licensed Oxford Gene Technology’s (OGT) Southern array patents covering the manufacture and commercialization of oligonucleotide arrays. In addition, NimbleGen will be able to make and sell OGT-designed arrays, and OGT will obtain DNA microarrays from NimbleGen, under a supply agreement between the two firms.

    “Successful discussions with NimbleGen have concluded with the granting of this license thus enabling NimbleGen to deliver their microarray products and services worldwide and adding to OGT’s growing portfolio of North American licensees,” says Sue Sutton, vp licensing North America at OGT.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »